Moderate to Severe Rheumatoid Arthritis – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Moderate to Severe Rheumatoid Arthritis Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Rheumatoid Arthritis Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Rheumatoid Arthritis Overview

Moderate to severe rheumatoid arthritis is a chronic autoimmune disorder in which persistent inflammation of the synovial lining leads to progressive joint damage, pain, stiffness, swelling, and functional disability, often accompanied by systemic complications such as cardiovascular disease, lung involvement, and fatigue. At these stages, patients experience significant impairment in daily activities, with disease activity measured through composite scores and biomarkers like rheumatoid factor and anti‑CCP antibodies. Management requires early, aggressive therapy with disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate, often combined with biologic or targeted synthetic agents including TNF inhibitors, IL‑6 receptor blockers, or JAK inhibitors, while corticosteroids and NSAIDs provide symptomatic relief. Despite advances, many patients continue to face flares and progression, underscoring the need for personalized treatment strategies, vigilant monitoring, and innovation in targeted therapies to preserve joint function, reduce systemic risks, and improve long‑term outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)